Concepts (143)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 17 | 2021 | 1535 | 1.950 |
Why?
|
| Antihypertensive Agents | 16 | 2021 | 498 | 1.680 |
Why?
|
| Blood Pressure | 15 | 2021 | 1451 | 1.500 |
Why?
|
| Acute Kidney Injury | 4 | 2019 | 232 | 0.800 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2019 | 161 | 0.710 |
Why?
|
| Kidney Diseases | 4 | 2018 | 307 | 0.680 |
Why?
|
| Arthroplasty, Replacement | 1 | 2019 | 48 | 0.630 |
Why?
|
| Creatine Kinase | 1 | 2018 | 46 | 0.610 |
Why?
|
| Glomerular Filtration Rate | 4 | 2019 | 274 | 0.530 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2018 | 202 | 0.480 |
Why?
|
| Drug Resistance | 3 | 2011 | 223 | 0.460 |
Why?
|
| Spironolactone | 1 | 2011 | 13 | 0.390 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2011 | 25 | 0.390 |
Why?
|
| Systole | 6 | 2020 | 149 | 0.360 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2010 | 73 | 0.350 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2010 | 31 | 0.350 |
Why?
|
| Diuretics | 4 | 2018 | 97 | 0.340 |
Why?
|
| Renal Dialysis | 1 | 2010 | 174 | 0.330 |
Why?
|
| Upper Extremity | 1 | 2010 | 112 | 0.330 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2010 | 186 | 0.320 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 212 | 0.310 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 940 | 0.300 |
Why?
|
| Aged | 16 | 2021 | 14862 | 0.280 |
Why?
|
| Treatment Outcome | 11 | 2019 | 7029 | 0.260 |
Why?
|
| Creatinine | 2 | 2019 | 243 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 365 | 0.230 |
Why?
|
| Risk Factors | 9 | 2020 | 5731 | 0.230 |
Why?
|
| Middle Aged | 16 | 2021 | 21147 | 0.230 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 31 | 0.220 |
Why?
|
| Male | 18 | 2021 | 37321 | 0.220 |
Why?
|
| Ramipril | 1 | 2002 | 10 | 0.210 |
Why?
|
| Humans | 23 | 2021 | 68618 | 0.210 |
Why?
|
| Indomethacin | 1 | 2002 | 107 | 0.200 |
Why?
|
| Drug Therapy, Combination | 5 | 2015 | 649 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2017 | 2007 | 0.190 |
Why?
|
| Female | 17 | 2021 | 38074 | 0.180 |
Why?
|
| Alabama | 2 | 2011 | 98 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 240 | 0.180 |
Why?
|
| Incidence | 3 | 2019 | 1603 | 0.180 |
Why?
|
| Aorta | 1 | 2021 | 316 | 0.170 |
Why?
|
| Accidental Falls | 1 | 2019 | 84 | 0.160 |
Why?
|
| Diabetes Complications | 1 | 2020 | 249 | 0.160 |
Why?
|
| Retrospective Studies | 4 | 2019 | 7277 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2018 | 138 | 0.150 |
Why?
|
| Sodium | 1 | 2018 | 161 | 0.150 |
Why?
|
| Chronic Disease | 3 | 2011 | 1330 | 0.140 |
Why?
|
| Logistic Models | 2 | 2011 | 1420 | 0.140 |
Why?
|
| Hypotension, Orthostatic | 1 | 2016 | 15 | 0.140 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1851 | 0.140 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2015 | 216 | 0.130 |
Why?
|
| Posture | 1 | 2016 | 107 | 0.130 |
Why?
|
| Blood Pressure Determination | 4 | 2018 | 152 | 0.130 |
Why?
|
| Sympathetic Nervous System | 1 | 2015 | 81 | 0.130 |
Why?
|
| Diet | 1 | 2018 | 514 | 0.120 |
Why?
|
| Time Factors | 4 | 2018 | 4655 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2019 | 2358 | 0.110 |
Why?
|
| Proteinuria | 2 | 2003 | 136 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 792 | 0.100 |
Why?
|
| Drug Chronotherapy | 1 | 2011 | 2 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 3 | 2018 | 195 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 4848 | 0.100 |
Why?
|
| Benzopyrans | 1 | 2011 | 21 | 0.100 |
Why?
|
| Ethanolamines | 1 | 2011 | 33 | 0.100 |
Why?
|
| Drug Resistance, Multiple | 1 | 2011 | 56 | 0.100 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2011 | 29 | 0.100 |
Why?
|
| Hyperkalemia | 1 | 2011 | 21 | 0.100 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 79 | 0.100 |
Why?
|
| Prevalence | 3 | 2011 | 1619 | 0.090 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 95 | 0.090 |
Why?
|
| Potassium | 1 | 2011 | 168 | 0.090 |
Why?
|
| Life Style | 2 | 2009 | 338 | 0.090 |
Why?
|
| Age Factors | 2 | 2016 | 1864 | 0.090 |
Why?
|
| Hyperaldosteronism | 1 | 2009 | 5 | 0.090 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2009 | 2 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 546 | 0.090 |
Why?
|
| Pheochromocytoma | 1 | 2009 | 22 | 0.090 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2009 | 26 | 0.090 |
Why?
|
| Renal Artery Obstruction | 1 | 2009 | 29 | 0.090 |
Why?
|
| United States | 4 | 2018 | 7367 | 0.080 |
Why?
|
| Adult | 7 | 2020 | 21403 | 0.080 |
Why?
|
| Myocardial Infarction | 3 | 2018 | 807 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2010 | 880 | 0.080 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2009 | 142 | 0.070 |
Why?
|
| Kidney | 1 | 2011 | 945 | 0.070 |
Why?
|
| Biomarkers | 1 | 2011 | 1593 | 0.060 |
Why?
|
| Obesity | 2 | 2009 | 1076 | 0.060 |
Why?
|
| Prognosis | 1 | 2009 | 2093 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 848 | 0.060 |
Why?
|
| Sex Factors | 2 | 2018 | 1266 | 0.060 |
Why?
|
| Lisinopril | 1 | 2003 | 16 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2015 | 89 | 0.050 |
Why?
|
| Dextrans | 1 | 2002 | 33 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2003 | 86 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 2002 | 155 | 0.050 |
Why?
|
| Heart Rate | 2 | 2015 | 568 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 3259 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2021 | 83 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1054 | 0.040 |
Why?
|
| Heart Failure | 2 | 2018 | 1180 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 1745 | 0.040 |
Why?
|
| Risk | 1 | 2019 | 563 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2018 | 108 | 0.040 |
Why?
|
| Kidney Function Tests | 2 | 2011 | 114 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2017 | 31 | 0.040 |
Why?
|
| Reference Standards | 1 | 2017 | 115 | 0.040 |
Why?
|
| Registries | 1 | 2021 | 733 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2019 | 737 | 0.040 |
Why?
|
| Diastole | 1 | 2017 | 161 | 0.040 |
Why?
|
| Sodium, Dietary | 2 | 2009 | 31 | 0.040 |
Why?
|
| Body Height | 1 | 2016 | 67 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 567 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2015 | 3705 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 1038 | 0.030 |
Why?
|
| Normetanephrine | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 9 | 0.030 |
Why?
|
| Cardiography, Impedance | 1 | 2015 | 14 | 0.030 |
Why?
|
| Critical Care | 1 | 2017 | 263 | 0.030 |
Why?
|
| Stroke | 2 | 2018 | 2163 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 955 | 0.030 |
Why?
|
| Vascular Resistance | 1 | 2015 | 179 | 0.030 |
Why?
|
| Adolescent | 2 | 2003 | 8912 | 0.030 |
Why?
|
| Nebivolol | 1 | 2011 | 6 | 0.030 |
Why?
|
| Anthropometry | 1 | 2011 | 64 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 260 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2279 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 289 | 0.020 |
Why?
|
| Internationality | 1 | 2008 | 74 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1738 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1426 | 0.020 |
Why?
|
| Weight Loss | 1 | 2009 | 319 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 714 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 1056 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 805 | 0.010 |
Why?
|
| Hypoalbuminemia | 1 | 2003 | 9 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 41 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2003 | 112 | 0.010 |
Why?
|
| Triglycerides | 1 | 2003 | 184 | 0.010 |
Why?
|
| Hypotension | 1 | 2003 | 74 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2003 | 161 | 0.010 |
Why?
|
| Cholesterol | 1 | 2003 | 331 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 5717 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2003 | 705 | 0.010 |
Why?
|